|Bid||10.90 x 1000|
|Ask||11.39 x 900|
|Day's range||10.46 - 11.30|
|52-week range||6.54 - 49.51|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
If so, it was probably for something like Berkshire Hathaway (NYSE: BRK.A), with an eye-popping price of $419,020 per share. Thankfully, there are much cheaper companies to buy, and some of them might even grow a bit faster than Warren Buffett's business. With its shares trading for around $13, having gained 139% in the past 12 months, Catalyst Pharmaceuticals (NASDAQ: CPRX) is a little-known biotech stock that's positioned to keep paying off for investors thanks to its progress in treating a rare neuromuscular disease called Lambert-Eaton myasthenic syndrome (LEMS).
It's risky, and you'll need to wait a while for a payoff, assuming the stars align for there to be one.
With shares of growth stocks significantly underperforming the market since September of last year, it's bargain-hunting season for investors who are comfortable with taking risks. With that in mind, let's investigate a pair of businesses that aren't exactly down on their luck even if their stocks are down, since either one could be a brilliant purchase for an enterprising investor. Shares of Compass Pathways (NASDAQ: CMPS) are down by 54% in the last 12 months.